Search the Newsreel

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com

The article reports that Whitehawk Therapeutics Inc. filed a Form 8K on August 6, 2026. This filing is a standard requirement by the SEC for companies to announce major events that shareholders should know about. The article provides the filing date and company name, …

Whitehawk Therapeutics, Inc. (WHWK) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive information on Whitehawk Therapeutics, Inc. (WHWK), a clinical-stage oncology therapeutics company. It includes real-time stock price data, historical performance, key financial metrics, company overview, recent news, analyst insights, and comparison tools with similar biotechnology companies. The stock showed …

Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028

Whitehawk Therapeutics reported a Q2 2026 net loss of $16.6 million, a significant reduction from the $52.6 million loss in Q2 2025. The company held $190.0 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which is expected to fund …

Whitehawk Q2 2026 earnings: Cash runway extends into the second half of 2028

Whitehawk Therapeutics reported no revenue in Q2 2026, but significantly narrowed its net loss per share to $0.20 due to the absence of a large prior-year license fee. A private placement boosted cash reserves to $190.0 million, extending the company's cash runway into the …

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Akari Therapeutics has announced a strategic research collaboration with Whitehawk Therapeutics to evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i platform for developing advanced Antibody-Drug Conjugates (ADCs). The collaboration aims to assess dual payload compatibility and synergies, with initial preclinical studies guiding …

Akari and Whitehawk to Test Two ADC Payloads in Preclinical Studies

Akari Therapeutics has announced a strategic research collaboration with Whitehawk Therapeutics to conduct preclinical studies. The collaboration will evaluate combining Akari's proprietary PH1 spliceosome-modulating payload with Whitehawk's topoisomerase I inhibitor (TOP1i) ADC platform to develop potential first-in-class dual-payload antibody-drug conjugates (ADCs) for cancer treatment. …

Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News

This article provides stock options chain information, quotes, and news for Whitehawk Therapeutics (WHWK). The content is a placeholder document, indicating that detailed financial data and news updates for WHWK would typically be found here.

Whitehawk Therapeutics (WHWK) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary

Whitehawk Therapeutics (WHWK) presented insights from its 7th Annual Oncology Innovation Summit, focusing on its advanced Antibody-Drug Conjugate (ADC) platform. The company highlighted its unique paired linker payload system (CPT113) designed for enhanced stability and targeted release of a Topo 1 inhibitor, aiming for …